Gujarat Themis Biosyn reported a 22% year-on-year increase in standalone net profit to ₹11.07 crore for the quarter ended June 30, 2026, driven by a 22% rise in income from operations to ₹43.79 crore. The Board of Directors approved the unaudited financial results on August 7, 2026, following a review by the Audit Committee and statutory auditors GMJ & Co. Management attributed the growth to healthy sales volumes and improved operational efficiency, which helped boost margins despite higher employee and other costs. This performance underscores the company’s strengthening position in the fermentation-based pharmaceutical intermediates sector.
The company’s earnings before interest, tax, depreciation, and amortization (EBITDA) surged 49% to ₹20.79 crore, with EBITDA margin expanding by 867 basis points to 47.5% from 38.8% in the corresponding quarter of FY26. Profit before tax rose 25% to ₹15.17 crore. Total expenses increased marginally by 4.8% to ₹23.00 crore, primarily due to a 52% year-on-year rise in employee benefit expenses to ₹4.72 crore and higher other costs. Finance costs also saw a sharp increase to ₹1.79 crore from ₹0.04 crore in Q1FY26, reflecting increased debt utilization for ongoing capex projects.
Key Financial Metrics
| Metric |
Q1FY27 (₹ Cr) |
Q4FY26 (₹ Cr) |
Q1FY26 (₹ Cr) |
| Income from Operations |
43.79 |
44.23 |
35.87 |
| EBITDA |
20.79 |
19.36 |
13.92 |
| EBITDA Margin (%) |
47.5% |
43.8% |
38.8% |
| Profit Before Tax |
15.17 |
14.34 |
12.12 |
| Net Profit After Tax |
11.07 |
10.89 |
9.06 |
| EPS (₹) |
1.02 |
1.00 |
0.83 |
The consolidated results mirrored the standalone figures as newly incorporated subsidiaries—Themis Biosyn Japan Limited and Themis Biosyn Ireland Private Limited—had not commenced operations. The company operates in a single segment manufacturing fermentation-based pharmaceutical intermediates and APIs, with no reportable segments under Ind AS-108.
Strategic Expansion and Inorganic Growth
Management highlighted significant strides in inorganic expansion. The company is pursuing the acquisition of MicroBiopharm Japan Co., Ltd., valued at approximately JPY 21.5 billion (~₹1,300 crore), expected to close in Q2FY27 subject to regulatory approvals. This deal aims to broaden GTBL’s API and intermediates portfolio across oncology, immunosuppressants, and peptides, leveraging MicroBiopharm’s proprietary P450 enzyme library and plasmid DNA technologies.
Additionally, GTBL has entered into an agreement with Sanofi to acquire a select product portfolio comprising 13 established brands in tuberculosis and anti-infectives, valued at ~EUR 158 million. This asset-light acquisition includes brands, marketing authorizations, and dossiers, providing immediate access to regulated markets in over 55 countries. Dr. Sachin Patel, Managing Director, stated these moves are major milestones in evolving into a global CDMO player.
Operational Updates and Capacity Expansion
During the earnings conference call held on August 10, 2026, management provided updates on capacity utilization and future capex. The company has practically doubled its fermentation capacity, with the expanded facility expected to be fully operational by the end of August 2026. CFO Krupesh Patel noted that gross block increased from ₹62 crore in FY23 to ₹435 crore in FY26, including capital work in progress (CWIP). Of the incremental ₹370 crore added over three years, approximately ₹200 crore pertains to new fermentation and API facilities, targeting an asset turnover ratio of 1.4x to 1.5x.
Regarding the API block, management clarified that commercialization was delayed because intermediate production was fully contracted to existing customers. With the new fermentation capacity coming online, the company expects to begin producing APIs such as Rifapentine, Rifaximin, and others without cannibalizing existing supply contracts. Revenue contribution from these new capacities is anticipated to materialize in the second half of FY27.
Funding and Integration Strategy
To fund the MicroBiopharm acquisition, GTBL is exploring a mix of debt and equity, with plans to raise up to ₹1,000 crore through equity. Management indicated that interest costs in the target geographies are significantly lower than domestic rates, ensuring the acquired business remains cash flow positive. For the Sanofi portfolio, a three-year transition service agreement is in place to transfer marketing authorizations and manufacturing control step-by-step. Initially, products will be manufactured via contract manufacturing organizations (CMOs), with potential integration of GTBL’s own APIs into the supply chain once regulatory approvals are secured.
Promoter pledge levels, which stood at approximately 48.5% as of June 2026, are expected to decrease significantly within 12 to 15 months. Management also addressed the withdrawal of the proposed merger with Themis Medicare, stating the decision was made to focus exclusively on transforming GTBL into a fermentation-based CDMO rather than diluting resources with domestic formulation businesses.
What the Numbers Show
A notable divergence in the cost structure is visible in finance costs, which surged to ₹1.79 crore in Q1FY27 from just ₹0.04 crore in Q1FY26. This sharp increase suggests a potential shift in debt utilization or interest-bearing liabilities, even as overall revenue growth remained robust. Meanwhile, employee benefit expenses rose 52% year-on-year to ₹4.72 crore, indicating increased operational staffing or compensation costs amidst the revenue expansion. The balance sheet shows total borrowings rising to ₹128.06 crore as on March 31, 2026, from ₹29.64 crore in the previous year, supporting ongoing capex for new R&D, API units, and a hybrid renewable power plant.
Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE942C01045/abba9742-3a8c-4e7d-b12e-03687e92fb1e.pdf
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
